MiR-330-3p inhibits gastric cancer progression through targeting MSI1

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• MicroRNAs (miRNAs) are crucial regulators in tumor development.
• Gastric cancer (GC) progression involves complex molecular alterations.
• Understanding miRNA roles in GC is vital for therapeutic strategies.

Purpose of the Study:

• To investigate the role of miR-330-3p in gastric cancer.
• To identify the target genes and regulatory mechanisms of miR-330-3p in GC.
• To evaluate miR-330-3p as a potential tumor suppressor in GC.

Main Methods:

• Quantitative real-time PCR to assess miR-330-3p and MSI1 expression in GC cell lines and tissues.
• Cell proliferation, colony formation, and migration assays.
• Western blotting to analyze protein expression (E-cadherin, N-cadherin, vimentin, snail).
• Luciferase reporter assays to confirm direct targeting of MSI1 by miR-330-3p.
• Treatment with epigenetic modifiers (TSA, AZA) to investigate miR-330-3p regulation.

Main Results:

• miR-330-3p expression was significantly downregulated in gastric cancer tissues and cell lines.
• Overexpression of miR-330-3p suppressed gastric cancer cell proliferation, colony formation, and migration.
• miR-330-3p overexpression promoted E-cadherin and inhibited N-cadherin, vimentin, and snail expression.
• Musashi-1 (MSI1) was identified as a direct target of miR-330-3p and was upregulated in GC.
• MSI1 expression was inversely correlated with miR-330-3p levels in GC tissues.
• miR-330-3p expression increased upon treatment with TSA and AZA, suggesting epigenetic regulation via hypermethylation.

Conclusions:

• miR-330-3p functions as a tumor suppressor gene in gastric cancer.
• Downregulation of miR-330-3p in GC is partly mediated by epigenetic silencing.
• Targeting the miR-330-3p/MSI1 axis may offer a therapeutic strategy for gastric cancer.